NERV — Minerva Neurosciences Share News
0.000.00%
Last trade - 00:00Brief: Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates
Brief: Minerva Neurosciences - To Offer And Sell Up To $75 Million In Common Stock Through Leerink Partners
Brief: Minerva Announces Leadership Transition
Minerva Neurosciences Q4 net loss widens on non-cash financing charges
Brief: Minerva Neurosciences Q4 Net Income USD -283.668 Million
Brief: Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors
Minerva Neurosciences reports $2.7 mln Q3 net loss
U.S. STOCKS ON THE MOVE-RBB Bancorp, Hologic, Eversource
U.S. STOCKS ON THE MOVE-RBB Bancorp, Hologic, Eversource
U.S. STOCKS ON THE MOVE-Lockheed Martin, Truist Financial, Reddit
Minerva Neurosciences soars after co secures up to $200 million in private placement
Brief: Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Minerva Neurosciences Inc expected to post a loss of 90 cents a share - Earnings Preview
Brief: Minerva Neurosciences Q1 Net Income USD -3.753 Million
Minerva Neurosciences Inc expected to post a loss of $1.07 a share - Earnings Preview
Minerva Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Minerva Neurosciences Q4 Net Income USD -4.272 Million
Minerva Neurosciences Inc expected to post a loss of $1.05 a share - Earnings Preview